NEW YORK, March 28 – Genometrix of The Woodlands, Texas, said Wednesday it had reached an agreement to provide SNP-discovery services for Agouron Pharmaceuticals, a subsidiary of Pfizer.
Genometrix did not disclose the terms of the deal, which resulted following a SNP-discovery pilot project.
Spokespeople for Genometrix and Agouron were not immediately available for comment.
Genometrix studies samples provided by its customers, analyzing them using its VistaMorph genotyping technology and its VistaLogic analysis and visualization tools.
SNPs are then screened against the company’s Population Diversity Panel to determine the distribution of the alleles in a diverse population.
Recently, Genometrix also signed animal genomics company AniGenics, as a customer. The company’s other customers include Schering-Plough, Proctor and Gamble, and VistaGen.